Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Shares of Corvus Pharmaceuticals, Inc. dropped nearly 8%, slipping to $19.68 in premarket trading Wednesday. The decline follows the company's announcement of an underwritten public offering worth $150 million in common stock and pre-funded warrants. These warrants let investors lock in shares now by paying most of the price upfront, with the option to buy later. Jefferies and Goldman Sachs are heading the deal, which also includes a 30-day over-allotment option allowing underwriters to purchase an extra $22.5 million in shares.

Biotechnology · NASDAQ:CRVS · Pharmaceuticals · Stock Market
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares edged down 0.2% to $124.68 in afternoon trade, after swinging between $122.49 and $126.22 earlier. Bernstein SocGen Group held firm on its Outperform rating and $135 price target, pointing to Yeztugo as a major driver for Gilead’s 2026 forecast. The firm also flagged that the market may be underestimating the boost from re-dosing planned for later this year.
20 January 2026
··
Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount, and key patents expire.
20 January 2026
···
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck & Co shares held steady on Tuesday following news that the company's personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda. By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating between $107.06 and $109.11.
20 January 2026
····
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid.
18 January 2026
····
1 … 21 22 23 24 25 … 50
Follow on Google News
Add as preferred source Open in Google News